Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CCKAR | P32238 | 1/20 | 0.39 |
| ▸ | CCKBR | P32239 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3740826 | 0.99 | ALDH1A1 (0.52) | ALDH1A1IDO1KDM4ESLC7A5TSHR | |
| Hydrochloric Acid SCHEMBL3740837 | 0.99 | ALDH1A1 (0.52) | ALDH1A1IDO1KDM4ESLC7A5TSHR | |
| SCHEMBL16604386 | 0.89 | ALDH1A1 (0.50) | ALDH1A1IDO1KDM4ESLC7A5USP2 | |
| SCHEMBL3751437 | 0.87 | KDM4E (0.49) | ALDH1A1IDO1KDM4ESLC7A5TSHR | |
| Hydrochloric Acid SCHEMBL16599926 | 0.87 | ALDH1A1 (0.52) | ALDH1A1IDO1KDM4ESLC7A5USP2 | |
| SCHEMBL6706478 | 0.87 | ALDH1A1 (0.53) | ALDH1A1IDO1KDM4ESLC7A5USP2 | |
| SCHEMBL16060230 | 0.87 | ALDH1A1 (0.53) | ALDH1A1IDO1KDM4ESLC7A5USP2 | |
| SCHEMBL16059778 | 0.87 | ALDH1A1 (0.53) | ALDH1A1IDO1KDM4ESLC7A5USP2 | |
| Hydrochloric Acid SCHEMBL3751435 | 0.86 | KDM4E (0.48) | ALDH1A1IDO1KDM4ESLC7A5TSHR | |
| Hydrochloric Acid SCHEMBL29728759 | 0.85 | ALDH1A1 (0.55) | ALDH1A1IDO1KDM4ESLC7A5USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855292-B2 | Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-21 | — | — | US | disclosed |
| US-20100292240-A1 | SULFONAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
| US-20080132511-A1 | Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics | JANSSEN PHARMACEUTICA NV (BE) | 2008-06-05 | — | — | US | disclosed |
| US-7297816-B2 | Sulfonamide compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-20 | — | — | US | disclosed |
| CN-101061116-A | Sulfonamide compounds | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-24 | — | — | CN | disclosed |
| EP-1797083-A1 | SULFONAMIDE COMPOUNDS | Janssen Pharmaceutica, N.V. (BE) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006036670-A1 | SULFONAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069286-A1 | Sulfonamide compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132511-A1 | Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics | CCKAR, CCKBR, GRPR | ALDH1A1 1954/4885IDO1 3043/4885KDM4E 4720/4885 |
| US-20100292240-A1 | SULFONAMIDE COMPOUNDS | CCKAR, CCKBR, TAS1R2 | ALDH1A1 2749/4885IDO1 3885/4885KDM4E 3780/4885 |
| US-20060069286-A1 | Sulfonamide compounds | CCKAR, CCKBR, TAS1R2 | ALDH1A1 2749/4885IDO1 3885/4885KDM4E 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.